Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Daclizumab in active relapsing multiple sclerosis
NCT00109161Phase 2Completed
- Sponsor
- PDL BioPharma
- Start
- Apr 2005
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
A Phase 2 trial of daclizumab in multiple sclerosis (MS), sponsored by PDL BioPharma. Started Apr 2005; status: completed.
02
Drugs
daclizumab
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT00109161.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00109161.